



Ceva Santé Animale announces new investment in its European vaccine production capacity with the creation of the EU's largest cryogenic storage facility in Monor, Hungary

23 November 2021 Monor, Hungary site - Ceva today announced the creation of a new state-of-the-art cryogenic storage facility at its Ceva Phylaxia subsidiary to meet rapidly growing demand for its vaccines. The Ceva Phylaxia campus in Budapest is the European arm of Ceva's global network of vaccine production and R&D centers, with other major campuses in the US, China, Germany and Brazil.

The new 44 Ha (440.000 m²) site, with the "Linilog warehouse" is situated in Monor, 40kms from the centre of Budapest and will stock deep frozen and semi-finished vaccines that must be stored in liquid nitrogen, at -196°C. Both the Hungarian Government and local Monor Municipality have supported Ceva's investment to ensure that the country remains at the forefront of Europe as a centre of excellence in biotechnology.

Over the last 5 years, the company has regularly invested in Hungary with the support of the Hungarian authorities. In October 2018, Ceva and the Hungarian Government signed a subsidy contract. Within this framework, Ceva is implementing greenfield investments (including Monor Linilog WH and related infrastructure) for a targeted amount of €26.3 millions. Ceva plans to continue investing in Hungary in the upcoming years.

Ceva Phylaxia currently employs 961 people, of which 141 work in innovation and development, the majority of them being researchers.

Commenting on Ceva's new investment, Ceva's Chairman & CEO, Dr. Marc Prikazsky said:

"Our new investment in Hungary has a significance that goes beyond the purely financial. 10 years ago, I committed Ceva to becoming a "One Health" company, investing first in preventative health. Since then we have transformed our business from being around 25% vaccines, to close to 50% today; I'm very proud of our teams here in Ceva Phylaxia who have played such an important role in that transformation."

More details:

The new warehouse facility is 4000 m² and at startup will house 80 freezers with an overall storage capacity of approx. 2.5m vaccine ampules but with sufficient space to more than double this. The Building Management and Air Handling Systems of the new facility were designed to ensure the right level of safety even for the future expanded capacities.

Ceva Santé Animale is the leading veterinary pharmaceutical company in France and the fifth largest in the world. Its driving force is innovation for the health of animals, humans and our environment. The Group develops medicines, vaccines, equipment and services for livestock (ruminants, pigs, poultry) and companion animals.
2020 turnover: €1.3 billion.

Website: www.ceva.com



Media Contacts:

Martin Mitchell, Group Communications Director martin.mitchell@ceva.com - +33 (0)5 57 55 40 80